Company: RPTX
Filing Date: 2025-12-03
Form Type: PREM14A
Source: 0001193125-25-306948
Chunk: 74

Company: Repare Therapeutics Inc.
Filing Date: 2025-12-03
Form: PREM14A
Chunk 74
---
 Partners then calculated the present value of the Cash Consideration and the Dissolution Payments as of November 14, 2025 by discounting the
Cash Consideration from January 31, 2026, and further discounting the December 31, 2025 present value of Dissolution Payments, to November 14, 2025 using the same 6.82% discount rate. Leerink Partners determined this discount rate
based upon its professional expertise and judgment.

This analysis resulted in an implied estimated present value as of November 14,
2025 of approximately $75 million, or $1.70 per Share, based on the assumed total shares outstanding of Repare of approximately 43.7 million as of November 13, 2025, as provided by Repare.

Leerink Partners then compared the results of the above analysis to the closing price of Repare Common Stock of $1.69 as of November 13,
2025, and present value of the Cash Consideration of $1.79 per Common Share.

General

Leerink Partners is a full-service securities firm engaged in securities trading and brokerage activities as well as investment banking and
financial advisory services. Since October 2025, Leerink Partners has served as sales agent under XRC’s at-the-market sales agreement, and has received de minimis
fees for such services. Except for the foregoing, during the past two years, Leerink Partners has not provided investment banking services to Repare, Parent or their respective affiliates. In the ordinary course of business, Leerink Partners may, in
the future, provide investment banking services to Repare, Parent, or their respective affiliates and would expect to receive customary fees for the rendering of such services. In the ordinary course of its trading and brokerage activities, Leerink
Partners has in the past held and may in the future hold positions, for its own account or the accounts of its customers, in equity, debt or other securities of Repare, Parent or their respective affiliates. Consistent with applicable legal and
regulatory requirements, Leerink Partners has adopted policies and procedures to establish and maintain the independence of its research department and personnel. As a result, Leerink Partners’ research analysts may hold views, make statements
or investment recommendations and/or publish research reports with respect to Repare, Parent, and the Transaction and other participants in the Transaction that differ from the views of Leerink Partners’ investment banking personnel.

The Repare Board selected Leerink Partners as a financial advisor in